UPDATE: The Interim Order No. 2 Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 was made on March 1, 2021 and repeals and replaces the Interim Order Respecting Drugs, Medical...more
4/22/2020
/ Canada ,
Clinical Trials ,
Controlled Substances ,
Coronavirus/COVID-19 ,
Expedited Approval Process ,
Food and Drug Act ,
Guidance Documents ,
Health Canada ,
Medical Devices ,
Personal Protective Equipment ,
Pharmacies ,
Prescribing Authority ,
Prescription Drugs ,
Public Health Emergency ,
Relief Measures ,
Temporary Regulations ,
Transparency ,
Vaccinations ,
Virus Testing
UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150)...
As previously reported, Justice O’Reilly of the Federal Court granted Pharmascience’s...more
4/17/2020
/ Appeals ,
Canada ,
Defense Strategies ,
Dismissals ,
Interlocutory Appeals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Popular ,
Section 8
In November 2019, we highlighted the key proposed amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA). The proposed amendments aim to reduce...more
2/10/2020
/ Canada ,
Drug Interchangeability and Dispensing Fee Act (DIDFA) ,
Final Rules ,
Payment Caps ,
Pharmaceutical Benefits Scheme ,
Pharmaceutical Industry ,
Pharmacies ,
Prescription Drugs ,
Product Labels ,
Proposed Amendments ,
Public Consultations ,
Rebates ,
Regulatory Burden
Update: On July 28, 2021, the Federal Court of Appeal dismissed Seedling’s appeal from Justice Grammond’s decision: Seedlings Life Science Ventures, LLC v Pfizer Canada ULC, 2021 FCA 154 (see article here).
On January 2,...more
2/6/2020
/ Anticipation ,
Canada ,
Claim Construction ,
Expert Testimony ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Popular
On October 28, 2019, the Ontario Ministry of Health and Long-Term Care (the Ministry) published proposed changes to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee...more
On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the...more
11/8/2019
/ Australia ,
Canada ,
Collaboration ,
Combination Products ,
Drug Approvals ,
Food and Drug Administration (FDA) ,
Health Canada ,
International Relations ,
Multinationals ,
Pharmaceutical Industry ,
Popular ,
Project Orbis
On August 8, 2019, the Court of Queen’s Bench of Alberta dismissed Allergan’s application for judicial review of a decision by the Alberta Minister of Health (the Minister) to designate Allergan’s glaucoma treatment product...more